Detection of progressive macular thickness loss using optical coherence tomography in glaucoma suspect and glaucomatous eyes.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE

Publication: <2003->: London : Nature Publishing Group
Original Publication: [London : Ophthalmological Society of the United Kingdom, 1987-

Glaucoma/*diagnosis ; Macula Lutea/*pathology ; Tomography, Optical Coherence/*methods; Adult ; Aged ; Analysis of Variance ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Regression Analysis

Aims: To examine the rate of macular thickness loss using time-domain optical coherence tomography (OCT) in functionally progressing versus non-progressing eyes, determined by standard automated perimetry (SAP).
Methods: Glaucoma suspects (GS) and glaucomatous (G) eyes underwent SAP and OCT imaging every 6 months. Functional progression was determined using pointwise linear regression, defined as 2 contiguous locations losing ≥1.0 dB/year at P<1.0% in the same hemifield. The annual rate of macular thickness loss was calculated from inner and outer regions of the macular map.
Results: 72 eyes (43 GS and 29G) with ≥30 months of follow-up were enrolled. Fourteen eyes demonstrated SAP progression. The annual rate of macular thickness loss (μm/year) in progressing eyes was faster (all P<0.05) than non-progressing eyes in temporal outer (-1.90±2.97 vs 0.33±2.77), nasal inner (-1.70±2.66 vs 0.14±2.76), superior inner (-2.15±4.57 vs 0.51±2.99), temporal inner quadrants (-2.58±5.05 vs -0.38±2.34), and the average of inner macular quadrants (-1.84±2.90 vs 0.03±2.10). The rate of loss in the nasal inner (P=0.02) and temporal outer (P=0.02) macular regions was associated with optic disc haemorrhage.
Conclusions: Eyes with SAP progression have significantly greater rates of macular thickness loss consistent with glaucomatous retinal ganglion cell atrophy, as compared with non-progressing eyes.

Ophthalmology. 2011 Aug;118(8):1551-7. (PMID: 21529958)
Br J Ophthalmol. 2003 Jun;87(6):726-30. (PMID: 12770970)
Arch Ophthalmol. 2011 May;129(5):562-8. (PMID: 21555607)
Ophthalmology. 1992 Jan;99(1):19-28. (PMID: 1741133)
Am J Ophthalmol. 1984 Nov;98(5):566-71. (PMID: 6496612)
Br J Ophthalmol. 2006 Nov;90(11):1393-7. (PMID: 16899526)
Arch Ophthalmol. 2003 Jan;121(1):48-56. (PMID: 12523884)
J Glaucoma. 2009 Mar;18(3):253-61. (PMID: 19295383)
Invest Ophthalmol Vis Sci. 1980 May;19(5):505-17. (PMID: 6154668)
J Glaucoma. 2008 Apr-May;17(3):183-8. (PMID: 18414102)
Ophthalmology. 1998 Feb;105(2):224-31. (PMID: 9479279)
Ophthalmology. 2005 Mar;112(3):366-75. (PMID: 15745761)
J Glaucoma. 2008 Oct-Nov;17(7):519-28. (PMID: 18854727)
J Glaucoma. 2012 Apr-May;21(4):214-20. (PMID: 21654510)
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):662-8. (PMID: 18824734)
Ophthalmology. 2009 Dec;116(12):2271-6. (PMID: 19854514)
Ophthalmology. 2005 Mar;112(3):391-400. (PMID: 15745764)
Invest Ophthalmol. 1973 Nov;12(11):814-29. (PMID: 4752920)
Ophthalmology. 2009 Dec;116(12):2305-14.e1-2. (PMID: 19744726)
Ophthalmology. 2008 Apr;115(4):661-666.e4. (PMID: 17706287)
Ophthalmology. 2003 Jan;110(1):177-89. (PMID: 12511364)
Am J Ophthalmol. 2004 Dec;138(6):1029-36. (PMID: 15629296)
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5741-8. (PMID: 19815731)
Am J Ophthalmol. 1989 May 15;107(5):453-64. (PMID: 2712129)
Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2242-50. (PMID: 10476789)
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):763-73. (PMID: 17251476)
Ophthalmology. 2011 Aug;118(8):1558-62. (PMID: 21529954)
Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2440-3. (PMID: 15980233)
Science. 1991 Nov 22;254(5035):1178-81. (PMID: 1957169)
Clin Exp Ophthalmol. 2012 May-Jun;40(4):e190-6. (PMID: 21902781)
Arch Ophthalmol. 2005 Apr;123(4):464-70. (PMID: 15824218)
Am J Ophthalmol. 2004 Aug;138(2):218-25. (PMID: 15289130)
Ophthalmology. 2007 Feb;114(2):205-9. (PMID: 17097736)
Ophthalmology. 2008 Sep;115(9):1557-65. (PMID: 18378317)
Am J Ophthalmol. 2006 Dec;142(6):1056-9. (PMID: 17157591)
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):217-22. (PMID: 19684001)
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30. (PMID: 12049574)
J Glaucoma. 2007 May;16(3):287-92. (PMID: 17438421)
Ophthalmology. 2011 Dec;118(12):2409-13. (PMID: 21885127)
Arch Ophthalmol. 2003 Jan;121(1):41-6. (PMID: 12523883)
Arch Ophthalmol. 1991 Jan;109(1):77-83. (PMID: 1987954)
Am J Ophthalmol. 2005 Jan;139(1):44-55. (PMID: 15652827)
Arch Ophthalmol. 2009 Dec;127(12):1603-9. (PMID: 20008715)

P30 EY014801 United States EY NEI NIH HHS; R01 EY013516-10 United States EY NEI NIH HHS; R01-EY013516 United States EY NEI NIH HHS; R01 EY013516 United States EY NEI NIH HHS; P30EY014801 United States EY NEI NIH HHS

Date Created: 20120512 Date Completed: 20120928 Latest Revision: 20211021

20240829

PMC3396176

10.1038/eye.2012.76

22576828